A bold truth: even in our high-profile world, early detection can change everything. Sir Cliff Richard has opened up about being treated for prostate cancer, sharing that the disease was found during a routine check-up tied to a tour. He emphasizes that the cancer was detected early and had not spread to other parts of his body.
During an appearance on ITV’s Good Morning Britain, the 85-year-old singer recounted how the early discovery occurred. He explained that while preparing for travel to Australia and New Zealand, a promoter requested proof of insurance and prompted a medical check. The tests revealed prostate cancer, but he reassures that it was relatively recent and had not metastasized—no spread to bones or other areas.
Sir Cliff also spoke with journalist Dermot Murnaghan, who in June disclosed that Murnaghan himself has stage four prostate cancer. Reflecting on his own experience, Cliff expressed uncertainty about recurrence but stressed the importance of ongoing testing and regular check-ups.
Beyond his personal experience, the musician expressed a desire to collaborate with the King on improving cancer screening for men. He pointed to the King’s recent mention of his own cancer treatment and the need for early detection, urging action on screening availability.
Cliff criticized the absence of a national screening program for prostate cancer, calling the situation “absolutely ridiculous.” He argued that governments should ensure all citizens have access to the same testing opportunities and early treatment, rather than offering selective preventive measures. His stance is that everyone deserves the chance to be tested early and treated promptly.
Sir Cliff is renowned for a catalog of hits spanning decades, including The Young Ones, We Don’t Talk Anymore, and Summer Holiday. In the broader screening debate, the National Screening Committee—the UK body that advises governments—has concluded that a universal prostate cancer screening program is not currently justified. Instead, they propose restricting screening to men with certain genetic mutations linked to more aggressive tumors.
A three-month public consultation began in late November as the committee weighs its final guidance to ministers across England, Wales, Northern Ireland, and Scotland. Each council will decide independently whether to implement a prostate cancer screening program.
Would you support a universal screening program for prostate cancer, or do you agree with a targeted approach based on genetic risk? Share your thoughts below.
